Colorectal cancer occurs in the colon or rectum. Mostly it begins as a growth, called a polyp, inside the colon or rectum. It effects men and women of all racial and ethnic groups and is largely found in people in the age group of 50 years and above. As per the latest market research report published by Technavio, the global colorectal cancer therapeutics market size will grow by USD 994.94 million during 2019–2023. Get the free sample report below for the detailed information.
Download the free sample report @ http://bit.ly/2Dc0RHW
Regenerative medicines such as gene therapy are some of the most advanced and heavily researched treatment methods. In gene therapy, the mutated gene is taken from the patient and is modified genetically in the laboratory, and then it is administered back into the patient. The genetically modified gene replaces the mutated genes. Currently, only seven gene therapies are approved globally, and these therapies have proven to be highly effective for the treatment of various indications.
As a result, companies are conducting clinical trials for the treatment of colorectal cancer. Which are still in the early phases. For instance, Tocagen is currently conducting Phase I study on Toca 511, a novel gene therapy, which consists of a purified retroviral replicating vector for encoding a modified yeast cytosine deaminase (CD) gene. Hence, the advent of gene therapy is expected to be a major trend in the global colorectal cancer therapeutics market to grow at a CAGR of 2.53% during the forecast period. To know the complete and in-depth analysis and forecast of this market get the complete report by clicking the link below.
Get the Complete Report @ http://bit.ly/2pSidqk